OneMedNet Corporation — Q3 2023 Form 10-Q
Business context and reporting period. OneMedNet provides clinical-imaging data and exchange services, primarily through its iRWD data offering and BEAM imaging-exchange platform. This filing covers the quarter and nine months ended September 30, 2023. The supplied filing text does not provide clear standalone three-month results; reported operating comparisons are for the nine-month period. The November 7, 2023 merger with Data Knights occurred after the reporting period.
Financial performance and position
| Metric | Nine months ended September 30, 2023 | Comparable period / reference |
|---|---|---|
| Revenue | $680,918 | $888,970 for 2022, per MD&A |
| Cost of revenue / gross loss | $812,202 / $(131,284) | 2022 comparable cost and gross profit are not clearly presented |
| Operating expenses | $4,280,122 | $3,537,121 shown in statements, but comparison period is unclear |
| Operating loss | $(4,411,406) | $(3,754,436) shown in statements, but comparison period is unclear |
| Net loss | $(4,957,647) | $(4,057,060) for 2022, per MD&A |
| Operating cash flow | $(4,712,547) | $(4,209,013), per MD&A comparison table |
| Cash and cash equivalents | $611,822 at September 30 | $270,859 at December 31, 2022 |
Gross margin was approximately negative 19.3%. Revenue declined about 23% year over year, which management attributed to an iRWD delivery delayed until the fourth quarter. The filing reports nine-month financing cash inflows of $5,082,310, mainly from convertible notes ($4,378,124) and shareholder loans ($704,000); capital spending was $28,801.
At September 30, current assets were $2,845,576, including $2,059,975 due from SPAC IPO costs, while current liabilities were $14,278,386—a working-capital deficit of approximately $11.4 million. Total liabilities were $17,676,282 and stockholders’ deficit was $14,738,338. Convertible-note principal was $13,865,000, with $1,193,896 of accrued interest; the balance sheet also reports a $704,000 related-party loan and $44,330 CEBA loan.
Changes, outlook, and risks
- Research and development expense was $1,133,149. Management says it increased investment in personnel and reclassified $294,083 of discovery-related curation costs from cost of revenue to R&D, affecting comparability.
- The company disclosed substantial doubt about its ability to continue as a going concern: cash was limited, operating cash flow was negative, and management said additional debt or equity financing and eventual profitability would be needed.
- Management expects significant future R&D, scaling, interest, and sales and marketing costs. It provided no quantified financial guidance in the supplied filing text.
- Convertible notes bear interest and include conversion provisions; noteholders may receive equity, creating potential dilution. The company also reported 4,219,848 outstanding warrants at September 30.
- Management cited competition for imaging data providers and life-sciences customers, financing constraints, and execution risks in expanding the provider network and commercializing iRWD. No material pending or threatened legal proceeding was reported.
- The post-period business combination was completed November 7. The filing states net cash received was $3,481.53 and identifies assumed extension and working-capital loans, among other items; these post-close amounts merit review.
Important facts for investors to verify
- The financial statements label comparisons as “year ended December 2022,” while MD&A presents some figures as nine-month 2022 comparisons; confirm the correct comparative periods and standalone Q3 results.
- MD&A says net loss increased by $900,587, or 18.2%; the stated dollar amounts imply a different percentage. Reconcile the calculation and related comparison figures.
- Confirm the collectability and timing of the $2.06 million SPAC-cost receivable, and the company’s cash runway and financing needs after the merger.
- Review the merger’s actual net proceeds, assumed obligations, convertible-note terms, and resulting share and warrant dilution.